Filament BioSolutions Partners with Canadian Academic Centers to Study Precision Nutritional Therapies

Filament BioSolutions Partners with Canadian Academic Centers to Study Precision Nutritional Therapies
Filament BioSolutions announced a partnership with the University of Ottawa and the Children’s Hospital of Eastern Ontario (CHEO) to conduct a $7.4 million study of clinical applications of microbiome-based precision nutrition for treating inflammatory bowel disease (IBD). Filament is a clinical nutrition company developing therapeutic nutrition products to improve patient health. In this project, Filament will support the development of nutrition-based therapies that use resistant starch for the targeted regulation of gut bacteria in IBD. The grant will fund the development of patient-specific treatment regimens based on individual microbiome (the population of gut bacteria) composition and function. The clinical nutrition company will lead activities related to the clinical, regulatory, product development, and commercialization strategies for these therapies. The initiative follows recent advances in the understanding of the microbiome’s involvement in IBD, which helps researchers now use the unique microbiome of each patient to identify optimal treatment strategies and to induce IBD remission. “We are thrilled to be corporate partners on this grant with our collaborators at the University of Ottawa, CHEO, and Biotagenics on this comprehensive proposal studying the interface of clinical nutrition and the microbiome. This is a major first step bringing us closer to developing a nutritional therapy candidate for a widely recognized unmet medical need in IBD that will improve quality of care for these patients," Tom Cirrito, chief executive officer of Filament, said in a
Subscribe or to access all post and page content.